Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEARCA:AORCVE:BCTCVE:ICONASDAQ:OKYO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORiShares Core Growth Allocation ETF$53.81-0.3%$54.64$47.56▼$55.74$1.98B0.62260,033 shs125,260 shsBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsICOiCo TherapeuticsC$0.11C$0.11C$0.02▼C$0.16C$952KN/A3.16 million shs1.31 million shsOKYOOKYO Pharma$1.45+2.8%$1.44$0.92▼$3.25$41.80M0.04153,700 shs3,435 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORiShares Core Growth Allocation ETF-0.22%+0.80%-2.51%+1.43%+8.68%BCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%ICOiCo Therapeutics0.00%0.00%0.00%0.00%0.00%OKYOOKYO Pharma-1.40%0.00%-3.42%-10.76%+10.16%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAORiShares Core Growth Allocation ETFN/AN/AN/AN/AN/AN/AN/AN/ABCTBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AICOiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOKYOOKYO Pharma2.4782 of 5 stars3.55.00.00.00.61.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORiShares Core Growth Allocation ETF0.00N/AN/AN/ABCTBriaCell TherapeuticsN/AN/AN/AN/AICOiCo TherapeuticsN/AN/AN/AN/AOKYOOKYO Pharma3.00Buy$7.00382.76% UpsideCurrent Analyst RatingsLatest ICO, OKYO, BXN, BCT, and AOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORiShares Core Growth Allocation ETFN/AN/AN/AN/AN/AN/ABCTBriaCell TherapeuticsN/AN/AC$3.34 per share3.17C$3.60 per shareN/AICOiCo TherapeuticsN/AN/AC$0.01 per share8.75C$0.00 per shareN/AOKYOOKYO PharmaN/AN/AN/AN/A($0.08) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORiShares Core Growth Allocation ETFN/AN/A17.21∞N/AN/AN/AN/AN/ABCTBriaCell TherapeuticsN/A-C$0.38N/A∞N/AN/AN/AN/AN/AICOiCo TherapeuticsN/A-C$0.01N/A∞N/AN/AN/AN/AN/AOKYOOKYO Pharma-$13.27MN/A0.00N/AN/AN/AN/AN/A8/20/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAORiShares Core Growth Allocation ETF$1.082.01%N/AN/AN/ABCTBriaCell TherapeuticsN/AN/AN/AN/AN/AICOiCo TherapeuticsN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORiShares Core Growth Allocation ETFN/AN/AN/ABCTBriaCell Therapeutics0.05129.63128.68ICOiCo TherapeuticsN/A1.141.12OKYOOKYO PharmaN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORiShares Core Growth Allocation ETFN/ABCTBriaCell TherapeuticsN/AICOiCo TherapeuticsN/AOKYOOKYO Pharma2.97%Insider OwnershipCompanyInsider OwnershipAORiShares Core Growth Allocation ETFN/ABCTBriaCell TherapeuticsN/AICOiCo TherapeuticsN/AOKYOOKYO Pharma40.46%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAORiShares Core Growth Allocation ETFN/A36.80 millionN/ANot OptionableBCTBriaCell Therapeutics515.91 millionN/ANot OptionableICOiCo TherapeuticsN/A9.07 millionN/ANot OptionableOKYOOKYO Pharma828.83 million17.17 millionNot OptionableICO, OKYO, BXN, BCT, and AOR HeadlinesSourceHeadlineOKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader eventproactiveinvestors.com - April 9 at 8:39 AMOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024globenewswire.com - April 8 at 7:00 PMOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgeryglobenewswire.com - April 2 at 7:00 AMJapan authorities inspect second Kobayashi Pharma factory after deathsmsn.com - March 31 at 9:46 PMJapan dietary supplement maker probes five deathsmsn.com - March 29 at 8:56 AMAnalysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB)markets.businessinsider.com - March 27 at 6:32 PMOKYO Pharma gains after positive results from Phase 2 dry eye disease trialmsn.com - March 22 at 3:14 PMRelief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Studymsn.com - March 22 at 3:14 PMOKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptomsproactiveinvestors.com - March 22 at 8:52 AMOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101globenewswire.com - March 22 at 7:00 AMOKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye diseaseproactiveinvestors.com - March 21 at 9:23 AMOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trialglobenewswire.com - March 21 at 7:00 AMOKYO Pharma to release Phase 2 dry eye disease trial results on Fridayproactiveinvestors.com - March 20 at 8:55 AMOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Eventglobenewswire.com - March 20 at 7:00 AMOKYO Pharma Limited (OKYO) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com - March 19 at 11:17 AMTokyo stocks open lower as gains locked in, BOJ outcome awaitedmsn.com - March 19 at 1:09 AMOKYO Pharma (OKYO) Price Target Increased by 20.00% to 6.12msn.com - February 25 at 8:55 AMTokyo stocks open flat as gains locked in, exporters risemsn.com - February 20 at 1:07 PMOKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trialproactiveinvestors.com - February 9 at 8:47 AMOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Painfinance.yahoo.com - February 9 at 8:00 AMPulling plug on Aduhelm in AD, Biogen turns resources to Leqembibioworld.com - February 2 at 1:16 PMStock market today: Asian shares mostly rise after Wall Street rebounds led by tech stocksmsn.com - February 2 at 1:16 PMOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Boardfinance.yahoo.com - January 31 at 8:20 AMEagles files lawsuit in patent dispute over cancer therapymsn.com - January 18 at 9:32 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesASML’s Earnings Could Bring The Stock to New HighsApril 16, 2024 10:20 AMView ASML’s Earnings Could Bring The Stock to New Highs5 Semiconductor Giants: Navigating the Recent PullbackApril 12, 2024 9:10 AMView 5 Semiconductor Giants: Navigating the Recent PullbackTaiwan Semiconductor Earnings: AI Dominance and Future OutlookApril 19, 2024 7:06 AMView Taiwan Semiconductor Earnings: AI Dominance and Future Outlook5 Trends You Need to Know This QuarterApril 13, 2024 9:16 AMView 5 Trends You Need to Know This QuarterGold Rush: Exploring 5 Sector Giants Amidst Soaring PricesApril 4, 2024 6:10 AMView Gold Rush: Exploring 5 Sector Giants Amidst Soaring PricesAll Headlines Company DescriptionsiShares Core Growth Allocation ETFNYSEARCA:AORiShares Growth Allocation ETF, formerly iShares S&P Growth Allocation Fund (the Fund), is an open-end management investment company. The Fund seeks investment results that correspond generally to the price and yield performance of the S&P Target Risk Growth Index (the Growth Allocation Index). The Growth Allocation Index seeks to measure the performance of an asset allocation strategy targeted to a growth-focused risk profile. The Fund is designed for investors seeking moderate capital appreciation and opportunity for current income and capital preservation. The Fund's investment advisor is BlackRock Fund Advisors.BriaCell TherapeuticsCVE:BCTBriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.iCo TherapeuticsCVE:ICOiCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed drug candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.OKYO PharmaNASDAQ:OKYOOKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
